Investor Update
Filed with ASX · · 15 pages · English
Summary by 6ix AI
Firebrick Pharma Limited has released an investor update detailing its current status and future plans for its Nasodine Nasal Spray product. The update highlights achievements in manufacturing and regulatory approvals, particularly in Southeast Asia, and outlines plans for further market expansion. Financial information, including cash balance and market capitalization, is also provided to give investors insight into the company's current standing.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/investor-update-68
Firebrick Pharma Limited on 6ix
Earlier from Firebrick Pharma
- March 2026 Quarterly Activity Report & Appendix 4C
- Firebrick Secures $1.5 million via Placement
- Trading Halt
- Registration Agreement and Approval of Nasodine in Indonesia
- Appendix 4D & Half-Year Financial Report to 31 December 2025
Later from Firebrick Pharma
- Appendix 4E and Annual Report 30 June 2026
- Firebrick receives $293,000 R&D Tax Incentive
- Firebrick announces USA Retail Launch Plan
- Firebrick Secures $732k in Strategic Investments
- Nasodine Nasal Spray Approved in the Philippines
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma